{
    "id": 60592,
    "name": "B-cell adult acute lymphocytic leukemia",
    "source": "DOID",
    "definition": "An adult acute ymphoblastic leukemia occurring in adults and that has_mateiral_basis_in B lymphocytes. [url:https\\://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C9143]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060592",
    "evidence": [
        {
            "id": 7034,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial supporting FDA approval, Besponsa (inotuzumab ozogamicin) treatment resulted in a significantly improved complete remission rate (80.7%, 88/109), duration of remission (4.6 months), progression free survival (5.0 months) and overall survival (7.7 months) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia when compared to standard of care (29.4%, 24/109, 3.1, 1.8, 6.7 months, respectively) (PMID: 27292104; NCT01564784).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3199,
                "therapyName": "inotuzumab ozogamicin",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6047,
                    "pubMedId": 27292104,
                    "title": "Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27292104"
                },
                {
                    "id": 15616,
                    "pubMedId": null,
                    "title": "Besponsa (inotuzumab ozogamicin) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12715,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taxol (paclitaxel) efficacy was enhanced when combined with Disarib, resulting in greater cell death compared to either agent alone in B-cell acute lymphocytic leukemia cells in culture (PMID: 27693384).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6603,
                "therapyName": "Disarib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10633,
                    "pubMedId": 27693384,
                    "title": "A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27693384"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15969,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Bosulif (bosutinib) resulted in decreased levels of BCR-ABL1 transcript after 7 weeks of treatment in an adult patient with Philadelphia chromosome (BCR-ABL1)-positive B-cell acute lymphoblastic leukemia harboring ABL1 Y440C, however, minimal residual disease remained (PMID: 30584318).",
            "molecularProfile": {
                "id": 31347,
                "profileName": "BCR - ABL1 ABL1 Y440C"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14104,
                    "pubMedId": 30584318,
                    "title": "A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30584318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15970,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an adult patient with Philadelphia chromosome (BCR-ABL1) positive B-cell acute lymphoblastic leukemia was found to have acquired an ABL1 Y440C mutation upon disease recurrence following Sprycel (dasatinib) therapy (PMID: 30584318).",
            "molecularProfile": {
                "id": 31347,
                "profileName": "BCR - ABL1 ABL1 Y440C"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14104,
                    "pubMedId": 30584318,
                    "title": "A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30584318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19546,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib mesylate) and Sprycel (dasatinib) co-administered with dexamethasone resulted in transient clinical benefit in a patient with B-cell acute lymphoblastic leukemia harboring RCSD1-ABL1, but the disease became refractory after subsequent acquirement of chromosomal translocations including t(5;16)(q33;q24), dic(18;20)(p11.2;q11.2), and t(10;19)(q24;p13.3) (PMID: 21863287).",
            "molecularProfile": {
                "id": 31012,
                "profileName": "RCSD1 - ABL1"
            },
            "therapy": {
                "id": 9065,
                "therapyName": "Dasatinib + Dexamethasone + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 17171,
                    "pubMedId": 21863287,
                    "title": "RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21863287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20787,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with B-cell acute lymphocytic leukemia harboring BCR-FGFR1 were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20788,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with B-cell acute lymphocytic leukemia harboring BCR-FGFR1 were resistant to treatment with Iclusig (ponatinib) in culture (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20789,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient with B-cell acute lymphocytic leukemia harboring BCR-FGFR1 were sensitive to treatment with GSK1838705A in culture, demonstrating inhibition of cell growth (PMID: 31980503).",
            "molecularProfile": {
                "id": 17379,
                "profileName": "BCR - FGFR1"
            },
            "therapy": {
                "id": 2739,
                "therapyName": "GSK1838705A",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18041,
                    "pubMedId": 31980503,
                    "title": "Functional characterization of two rare BCR-FGFR1+ leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31980503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20799,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B-cell acute lymphocytic leukemia cells harboring FLT3 R845G and FLT3 E598_Y599insFDFREYE were sensitive to treatment with Vanflyta (quizartinib), demonstrating decreased cell viability in culture (PMID: 30962949).",
            "molecularProfile": {
                "id": 35342,
                "profileName": "FLT3 E598_Y599insFDFREYE FLT3 R845G"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18045,
                    "pubMedId": 30962949,
                    "title": "Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20800,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B-cell acute lymphocytic leukemia cells harboring FLT3 R845G and FLT3 E598_Y599insFDFREYE were sensitive to treatment with Crenolanib, demonstrating decreased cell viability in culture (PMID: 30962949).",
            "molecularProfile": {
                "id": 35342,
                "profileName": "FLT3 E598_Y599insFDFREYE FLT3 R845G"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18045,
                    "pubMedId": 30962949,
                    "title": "Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01084252",
            "title": "Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 6357,
                    "therapyName": "Dexamethasone + Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02877303",
            "title": "Blinatumomab and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9108,
                    "therapyName": "Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9109,
                    "therapyName": "Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9110,
                    "therapyName": "Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9111,
                    "therapyName": "Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ofatumumab + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9112,
                    "therapyName": "Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02924402",
            "title": "Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7600,
                    "therapyName": "XmAb13676",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03441061",
            "title": "Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3199,
                    "therapyName": "inotuzumab ozogamicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03642626",
            "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7940,
                    "therapyName": "Cyclophosphamide + Fludarabine + Tisagenlecleucel",
                    "synonyms": null
                },
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03876769",
            "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03913559",
            "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3199,
                    "therapyName": "inotuzumab ozogamicin",
                    "synonyms": null
                },
                {
                    "id": 8175,
                    "therapyName": "Cytarabine + Hydrocortisone + Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 8161,
                    "therapyName": "Acetaminophen + Diphenhydramine + Methylprednisolone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03962465",
            "title": "Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8400,
                    "therapyName": "Daunorubicin + inotuzumab ozogamicin + Pegaspargase + Prednisone + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8399,
                    "therapyName": "Daunorubicin + inotuzumab ozogamicin + Prednisone + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04170283",
            "title": "Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2544,
                    "therapyName": "Zanubrutinib",
                    "synonyms": null
                }
            ]
        }
    ]
}